Patent Assignment
Reel/Frame 017596/0304
Assignment of Assignor's Interest
Recorded: 2006-05-10
Received: 2006-05-10
Pages: 46
Assignor
SHIRE LABORATORIES, INC
Executed: 2006-04-25
Assignee
SUPERNUS PHARMACEUTICALS, INC
1550 EAST GUDE DR, ROCKVILLE, MD, 20850, UNITED STATES
Covered Properties
(50)
Orally administrable extended release pellet and tablet formulations of a highly water soluble compound
Application:
11/296,212 →
Less Abusable Pharmaceutical Preparations
Application:
11/250,309 →
Controlled Release Compositions of Gamma-Hydroxybutyrate
Application:
11/239,638 →
Modified release tablet formulations with enhanced mechanical properties
Application:
60/703,000 →
Micellar systems useful for delivery of lipophilic or hydrophobic compounds
Application:
10/995,942 →
Compositions of quaternary ammonium compounds containing bioavailability enhancers
Application:
10/980,819 →
Once Daily Dosage Forms of Trospium
Application:
10/980,818 →
Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
Application:
10/980,820 →
Less abusable pharmaceutical preparations
Application:
60/619,589 →
Controlled release compositions of gamma-hydroxybutyrate
Application:
60/614,622 →
Micellar systems useful for the delivery of lipophilic or hydrophobic compounds
Application:
60/566,157 →
Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
Application:
10/822,949 →
Once Daily Formulations of Tetracyclines
Application:
10/819,620 →
Accelerated Culture System for Intestinal Epithelial Cell Monolayers
Application:
10/797,952 →
Once daily formulations of doxycycline
Application:
60/547,964 →
Drug Formulation and Delivery Using Crystalline Methylated Cyclodextrins
Application:
10/770,727 →
Micellar systems useful for delivery of lipophilic or hydrophobic compounds
Application:
60/541,389 →
Absorption enhancing agents
Application:
10/762,446 →
Use of a Mixture of Two or More Enteric Materials to Regulate Drug Release via Membrane or Matrix for Systemic Therapeutics
Application:
10/751,766 →
Micellar systems useful for delivery of lipophilic or hydrophobic compounds
Application:
60/525,572 →
Once daily dosage forms of trospium
Application:
60/523,968 →
Compositions of quaternary ammoniun compounds cotaining bioavailability enhancers
Application:
60/517,196 →
Once daily dosage forms of trospium
Application:
60/517,198 →
Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
Application:
60/517,170 →
Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
Application:
10/451,271 →
Osmotic Delivery of Therapeutic Compounds by Solubility Enhancement
Application:
10/655,725 →
Self-Emulsifying Formulations of Fenofibrate and/or Fenofibrate Derivatives with Improved Oral Bioavailability and/or Reduced Food Effect
Application:
10/607,719 →
Fluidization of Particles for Encapsulation in Oral Dosage Pharmaceutical Products
Application:
10/437,397 →
Drug formulations having reduced abuse potential
Application:
10/435,597 →
Pharmaceutical formulations with improved bioavailability
Application:
10/425,268 →
Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
Application:
60/462,830 →
Once daily formulations of doxycycline
Application:
60/460,963 →
Accelerated culture system for intestinal epithelial cell monolayers
Application:
60/455,236 →
Drug formulation and delivery using crystalline methylated cyclodextrins
Application:
60/444,455 →
Absorption enhancing agents
Application:
60/441,950 →
Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
Application:
60/437,800 →
Oral Capsule Formulation with Increased Physical Stability
Application:
10/324,954 →
Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
Application:
10/324,953 →
Soluble Form Osmotic Dose Delivery System
Application:
10/324,187 →
Self-emulsifying fenofibrate pharmaceutical formulation with enhanced oral bioavailability
Application:
60/392,791 →
Pharmaceutical Compositions Including Ace/Nep Inhibitors and Bioavailability Enhancers
Application:
10/134,651 →
Formulation with improved bioavailability due to increased gastric or intestinal residence
Application:
60/375,803 →
Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
Application:
10/061,804 →
Soluble Form Osmotic Dose Delivery System
Application:
10/035,077 →
Oral capsule formulation with increased physical stability
Application:
60/342,430 →
Sustained Release Pharmaceutical Dosage Forms with Minimized Ph Dependent Dissolution Profiles
Application:
10/027,349 →
System for Osmotic Delivery of Pharmaceutically Active Agents
Application:
09/872,173 →
Accelerated Montgomery Exponentiation Using Plural Multipliers
Application:
09/849,853 →
Pharmaceutical compositions including sampatrilat and ascorbic acid
Application:
60/287,535 →
Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
Application:
09/773,838 →